Nav: Home

Griffith scientists unlock the 'Malaria box'

August 01, 2016

Griffith University tropical disease researchers have joined together with a host of international laboratories to advance drug discovery for major topical diseases through the creation and testing of the Malaria Box.

In a paper published this week in the top journal PLoS Pathogens, the global team present findings on a panel of 400 chemical compounds -- dubbed the "Malaria Box" -- with potential application as therapeutic starting points for diseases like malaria, trypanosomiasis and toxoplasmosis.

Typically researchers would have been working on their own compounds but this shared collaboration opens new doors for international advances in drug discovery.

The search for new therapies for tropical diseases is of high importance due to a lack of effective vaccines, lack of drugs for some diseases or reduced efficacy of some drugs due to resistance.

Tropical diseases are an enormous health problem, impacting hundreds of millions of lives and killing millions annually. In 2015 the World Health Organisation reported that there were more than 200 million clinical cases of malaria alone, which resulted in an estimated 438,000 deaths. This translates to almost one death due to malaria every minute.

"The work presented in this paper represents a significant step forward in our ability to combat major tropical infectious diseases," says Griffith University researcher Professor Vicky Avery, who was instrumental in selection of the 400 chemical compounds that make up the Malaria Box.

Professor Avery is one of five researcher leaders from the Griffith Eskitis Institute for Drug Discovery who contributed to the global open source drug discovery initiative.

The teams' expertise spans the disciplines of biology and chemistry.

Malaria drug discovery researcher Associate Professor Kathy Andrews, who worked together with chemist Professor Sally-Ann Poulsen and cancer biologist Associate Professor Kathryn Tonissen on the project says: "If we are going to make a difference and help save lives with new drugs we need to think differently."

"The data presented in this paper will be an extremely valuable source of information for drug discovery researchers around the world -- not only those working on tropical diseases but also to those working on other infectious diseases and even cancer." Leading drug discovery researcher and chemist Professor Ron Quinn says the work is a great example of how the Eskitis Institute for Drug Discovery is bridging the gap between chemistry and biology to discover new ways to treat infectious diseases.

"Eskitis researchers are at the cutting edge of drug discovery for infectious diseases and we are delighted to be able to contribute to this important global collaboration," he says.

For more on the paper visit http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1005763.
-end-
The Eskitis Institute for Drug Discovery is one of Griffith University's top research centres with a focus on making a difference to human health through the discovery and development of new drugs for infectious diseases, cancers and neurological disorders.

Additional information about work being carried out at the Eskitis Institute for Drug Discovery and on how you can support this research can be found on the following websites:

https://www.griffith.edu.au/science-aviation/eskitis-institute

https://app.secure.griffith.edu.au/donations/info.php

Griffith University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...